Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synaptic Ras GTPase–activating protein 1 (SYNGAP1) is a major component of the postsynaptic density at excitatory synapses in the brain. It functions as a Ras/Rap GTPase activating enzyme, negatively regulating these small G-proteins, which are critical for intracellular signaling cascades involved in synapse formation, plasticity, and cognitive development. SYNGAP1 is essential for normal cognition, learning, memory, and proper maturation of dendritic spines. It acts as an inhibitory regulator within NMDA receptor complexes to control AMPA receptor insertion into the membrane—a key process underlying synaptic strength adjustments during learning. Mutations or loss-of-function variants in SYNGAP1 cause severe neurodevelopmental disorders including intellectual disability, epilepsy, autism spectrum disorder, and sensory processing abnormalities. The gene produces multiple isoforms through alternative splicing that can have distinct effects on neuronal signaling; knockout models demonstrate its necessity for survival and normal brain circuit formation[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synaptic Ras GTPase-activating protein 1 (SYNGAP1).